Second Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System
July 26 2017 - 8:30AM
Business Wire
- Marks Continued Global Expansion of Argus
II for Individuals Blinded by Retinitis Pigmentosa -
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second
Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics to provide useful vision to blind
patients, today announced market entry into Russia, implanting the
first patient with the Company’s Argus® II Retinal Prosthesis
System (“Argus II”) in Moscow. The implant was facilitated by the
country’s exclusive distribution partner, Medical Equipment Trading
Company. The project was initiated by the Deaf-Blind Support
Foundation Con-nection and supported by the Art, Science and Sport
Charity Foundation and the Laboratory "Sensor-Tech" from
Moscow.
“This first implant in Russia represents an important step as we
seek to expand our global presence and make the Argus II available
to more blind individuals worldwide. We are excited about the
long-term potential of new markets, like Russia as well as our
recent entry into South Korea and Taiwan,” said Will McGuire, Chief
Executive Officer of Second Sight.
The first implant in Russia was performed at the Federal State
Institution & Clinical Research Center of the Federal
Medico-Biological Agency (FMBA) by a surgical team at the end of
June 2017 in Moscow in a 59-year-old patient with Retinitis
Pigmentosa. Dr. Paulo Stanga, Ophthalmologist &
Vitreoretinal Surgeon at the Manchester Royal
Eye Hospital, UK proctored the surgery.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation
that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe
to profound Retinitis Pigmentosa. The Argus II works by converting
images captured by a miniature video camera mounted on the
patient's glasses into a series of small electrical pulses, which
are transmitted wirelessly to an array of electrodes implanted on
the surface of the retina. These pulses stimulate the retina's
remaining cells, intending to result in the perception of patterns
of light in the brain. The patient must learn to interpret these
visual patterns, having the potential to regain some visual
function. The Argus II was the first artificial retina to receive
widespread approval, and is offered at approved centers in Canada,
France, Germany, Italy, Russia, Saudi Arabia, South Korea, Spain,
Taiwan, Turkey, United Kingdom, and the U.S.
About Second Sight
Second Sight's mission is to develop, manufacture and market
innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has
developed and manufactures the Argus® II Retinal Prosthesis System.
Second Sight is currently conducting a trial to test the safety and
utility of the Argus II in individuals with Dry Age-Related Macular
Degeneration. Second Sight is also developing the Orion™ I
Visual Cortical Prosthesis that is intended to restore some vision
to individuals who are blind due to many causes other than
preventable or treatable conditions. U.S. Headquarters are in
Sylmar, CA, and European Headquarters are in Lausanne, Switzerland.
For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange
Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this
release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as
"estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should"
and similar expressions or the negative versions thereof and which
also may be identified by their context. All statements that
address operating performance or events or developments that Second
Sight expects or anticipates will occur in the future, or that are
not otherwise historical facts, are forward-looking statements.
While management has based any forward looking statements included
in this release on its current expectations, the information on
which such expectations were based may change. Forward-looking
statements involve inherent risks and uncertainties which could
cause actual results to differ materially from those in the
forward-looking statements, as a result of various factors
including those risks and uncertainties described in the Risk
Factors and in Management's Discussion and Analysis of Financial
Condition and Results of Operations sections of our Annual Report
on Form 10-K as filed on March 16, 2017, and our other
reports filed from time to time with the Securities and
Exchange Commission. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170726005611/en/
Investor Relations:Institutional
InvestorsIn-Site Communications, Inc.Lisa Wilson,
212-452-2793Presidentlwilson@insitecony.comorIndividual InvestorsMZ North AmericaGreg Falesnik,
949-385-6449Managing Directorgreg.falesnik@mzgroup.us
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Aug 2024 to Sep 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Sep 2023 to Sep 2024